Stocks · News reference
Revelation Biosciences shares are trading lower after the company announced a 1-for-7 reverse stock split, effective October 20.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Revelation Biosciences Selected Avance Clinical To Serve As CRO For Phase 2/3 Adaptive-Design TITAN Study For Evaluating Gemini In Patients With Acute Kidney Injury
– Study on track to begin later this year –Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat
Revelation Biosciences Q2 EPS $(0.87) Beats $(0.88) Estimate
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(0.88) by 1.14 percent. This is a 87.59 percent increase over losses of $(7.01) per share